Conv. Plasma
Nigella Sativa

All azvudine studies
Meta analysis
study COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Recovery time -12% Improvement Relative Risk Viral clearance 32% Azvudine for COVID-19  Chen et al.  EARLY TREATMENT Is early treatment with azvudine beneficial for COVID-19? Retrospective 207 patients in China (August - October 2022) Improved viral clearance with azvudine (p=0.044) Chen et al., medRxiv, January 2023 Favors azvudine Favors control

Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study

Chen et al., medRxiv, doi:10.1101/2023.01.05.23284180
Jan 2023  
  Source   PDF   All   Meta
Azvudine for COVID-19
41st treatment shown to reduce risk in July 2023
*, now known with p = 0.00014 from 18 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 207 COVID-19 patients in China, showing azvudine associated with faster viral clearance, with azvudine-treated patients obtaining a negative PCR test result 1.7 days faster on average compared to supportive care alone after adjusting for age and sex.
recovery time, 12.5% higher, relative time 1.12, p = 0.94, treatment 66, control 41.
risk of no viral clearance, 31.6% lower, HR 0.68, p = 0.04, treatment 166, control 41, adjusted per study, inverted to make HR<1 favor treatment, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 6 Jan 2023, retrospective, China, preprint, 7 authors, study period August 2022 - October 2022. Contact:,
This PaperAzvudineAll
Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study
Wenmei Chen, Honggang Xu, Lei Hong, Ran Yang, Caiqiu Peng, Guiqiang Wang, Prof Wei Li
Background: There is a lack of data on the efficacy of oral Azvudine in Coronavirus Disease treatment. This study aimed to assess the association between Azvudine treatment and clinical outcomes in a cohort of patients infected with the SARS-CoV-2 Omicron variant. Methods: This is a retrospective study conducted in two mobile cabin hospitals. All consecutive patients with a diagnosis of COVID-19 admitted from August to October 2022 were included in the study. Linear regression models and Cox proportional hazards models were used to assess the association between Azvudine treatment and time to obtain the first negative nucleic acid test results. Results: A total of 207 patients were analyzed, of whom 166 patients (80.2%) received Azvudine treatment after hospitalization, and the rest did not. Linear regression models showed that Azvudine treatment was associated with reduced time to obtain the first negative nucleic acid test results after adjusting for age and gender [mean difference = -1.658; 95% CI: -2.772 to -0.544, P = 0.0039]. The multivariable Cox analysis conforms to the results from the linear regression model (hazard ratio = 1.461; 95% CI: 1.01 to 2.11, P = 0.044). Conclusion: Azvudine treatment was associated with reduced virus shedding time. Further studies are needed to confirm our findings.
Declarations Acknowledgment: None. Competing interest: The authors declare no competing interests. Authors' contributions: WL, GQW equally contributed to the conception and design of the research. WMC, HGX, LH, RY and CQP performed the research and analyzed the data. WMC, HGX and LH wrote the manuscript and interpretation of data. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript. Ethics statement: This study was approved by the institutional review board of the First Affiliated Hospital of Bengbu Medical College with a waiver of consent for the the retrospective observational design (No. 2020KY112, 2020KY016). Data are presented as n (%) or median (interquartile range).
Arbel, Sagy, Hoshen, Battat, Lavie et al., Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge, N Engl J Med
Brussow, COVID-19: Omicron -the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2, Microb Biotechnol
Chang, 4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives, Acc Chem Res
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med
Guo, Han, Zhang, He, Yu et al., SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance, Front Immunol
Huang, Wu, Zheng, Xie, He et al., Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1, BA.2/BA.3. Immunity
Lin, Wu, Li, Bian, Li et al., Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China, J Med Virol
Mccallum, Czudnochowski, Rosen, Zepeda, Bowen et al., Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement, Science
Ren, Luo, Yu, Song, Liang et al., A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study, Adv Sci (Weinh)
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Xu, Chen, Tang, Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China, Glob Health Med
Xu, Li, You, Zhang, Li et al., Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: Real-world study in Jilin Province, China, Emerg Microbes Infect
Ying-Hao, Yuan-Yuan, Dong, Qiu-Hua, Xue-Ran et al., Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: A retrospective study of 25207 cases in a Fangcang hospital, Front Cell Infect Microbiol
Yu, Chang, Azvudine (FNC): a promising clinical candidate for COVID-19 treatment, Signal Transduct Target Ther
Yu, Chang, The first Chinese oral anti-COVID-19 drug Azvudine launched, Innovation (Camb)
Zhang, Li, Wang, Liu, Lu et al., Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal Transduct Target Ther
Zhu, Zhang, Li, Yang, Song, A Novel Coronavirus from Patients with Pneumonia in China, N Engl J Med
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop